A phase 1 study of MEDI3617, a selective angiopoietin-2 inhibitor, alone and in combination with carboplatin/paclitaxel, paclitaxel, or bevacizmab in patients with advanced solid tumors Meeting Abstract

  

Authors:	Hyman, D. M.; Rizvi, N. A.; Natale, R. B.; Armstrong, D. K.; Birrer, M. J.; Recht, L. D.; Dotan, E.; Gribbin, M. J.; McDevitt, J. T.; Tavakkoli, F.; McCaffrey, J.; Sikorski, R.; Lai, D. W.
Abstract Title:	A phase 1 study of MEDI3617, a selective angiopoietin-2 inhibitor, alone and in combination with carboplatin/paclitaxel, paclitaxel, or bevacizmab in patients with advanced solid tumors
Meeting Title:	50th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	32
Issue:	15 Suppl.
Meeting Dates:	2014 May 30-Jun 3
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2014-05-20
Language:	English
ACCESSION:	WOS:000358613202903
PROVIDER:	wos
DOI:	10.1200/jco.2014.32.15_suppl.3012
Notes:	Meeting Abstract: 3012 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/80934